US SB4535 | 2021-2022 | 117th Congress
Status
Spectrum: Partisan Bill (Republican 1-0)
Status: Introduced on July 14 2022 - 25% progression, died in committee
Action: 2022-07-14 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on July 14 2022 - 25% progression, died in committee
Action: 2022-07-14 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Pending: Senate Health, Education, Labor, And Pensions Committee
Text: Latest bill text (Introduced) [PDF]
Summary
A bill to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs, medical devices, generic drugs, and biosimilar biological products, and for other purposes.
Title
FDASRA Act of 2022 Food and Drug Administration Simple Reauthorization Act of 2022 Biosimilar User Fee Amendments of 2022 Generic Drug User Fee Amendments of 2022 Medical Device User Fee Amendments of 2022 Prescription Drug User Fee Amendments of 2022
Sponsors
| Sen. Richard Burr [R-NC] |
History
| Date | Chamber | Action |
|---|---|---|
| 2022-07-14 | Senate | Read twice and referred to the Committee on Health, Education, Labor, and Pensions. |
Same As/Similar To
HB7667 (Related) 2022-06-09 - Received in the Senate.
SB4348 (Related) 2022-07-13 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
HB6833 (Related) 2022-09-30 - Motion to reconsider laid on the table Agreed to without objection.
SB4348 (Related) 2022-07-13 - Placed on Senate Legislative Calendar under General Orders. Calendar No. 444.
HB6833 (Related) 2022-09-30 - Motion to reconsider laid on the table Agreed to without objection.
Subjects
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/117th-congress/senate-bill/4535/all-info |
| Text | https://www.congress.gov/117/bills/s4535/BILLS-117s4535is.pdf |
